HUADONG MEDICINE CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.77 CNY | +0.06% |
|
+4.03% | -20.96% |
| Apr. 25 | Huadong Medicine Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Apr. 18 | Huadong Medicine's 2023 Profit Jumps 14% | MT |
| Sales 2024 * | 45.58B 6.29B | Sales 2025 * | 49.97B 6.9B | Capitalization | 57.35B 7.92B |
|---|---|---|---|---|---|
| Net income 2024 * | 3.47B 479M | Net income 2025 * | 4.13B 570M | EV / Sales 2024 * | 1.17 x |
| Net cash position 2024 * | 3.97B 548M | Net cash position 2025 * | 6.09B 840M | EV / Sales 2025 * | 1.03 x |
| P/E ratio 2024 * |
16.5
x | P/E ratio 2025 * |
13.9
x | Employees | 16,969 |
| Yield 2024 * |
2.04% | Yield 2025 * |
1.84% | Free-Float | 41.86% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +0.06% | ||
| 1 week | +4.03% | ||
| Current month | +5.71% | ||
| 1 month | +5.64% | ||
| 3 months | +3.83% | ||
| 6 months | -17.87% | ||
| Current year | -20.96% |
1 week
31.58
33.35
1 month
28.9033.35
Current year
27.6041.45
1 year
27.6046.43
3 years
27.6053.94
5 years
16.0253.94
10 years
11.6753.94
| Managers | Title | Age | Since |
|---|---|---|---|
Hong Lan Ma
DFI | Director of Finance/CFO | 53 | - |
Bang Liang Li
CHM | Chairman | 78 | 71-12-31 |
Dong Zhou Liu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cheng Wei Liu
BRD | Director/Board Member | 50 | 02-12-31 |
Bang Liang Li
CHM | Chairman | 78 | 71-12-31 |
Wei Kang
BRD | Director/Board Member | 56 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.41% | 2 M€ | -16.59% | - | |
| 0.99% | 2 M€ | -14.14% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 32.77 | +0.06% | 17,618,520 |
| 24-04-25 | 32.75 | +1.08% | 16,562,600 |
| 24-04-24 | 32.4 | -1.79% | 13,358,980 |
| 24-04-23 | 32.99 | +3.68% | 20,709,810 |
| 24-04-22 | 31.82 | +1.02% | 13,485,220 |
End-of-day quote Shenzhen S.E., April 25, 2024
More quotes
Huadong Medicine Co., Ltd. specializes in the development, manufacture and marketing of medical products and vaccines. The products are intended primarily for the treatment of tumors, immune disorders, endocrine disorders, orthopedic and traumatological disorders, digestive system diseases and viral diseases.
Sector
Pharmaceuticals
Calendar
2024-05-08
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
32.77
CNY
Average target price
47.85
CNY
Spread / Average Target
+46.03%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.96% | 7.91B | |
| +17.35% | 71.39B | |
| +5.38% | 8.59B | |
| +6.69% | 8.19B | |
| +0.49% | 4.54B | |
| +17.12% | 4.31B | |
| -3.38% | 3.93B | |
| -2.61% | 3.86B | |
| +22.08% | 3.64B | |
| +7.96% | 3.29B |
- Stock Market
- Equities
- 000963 Stock
